Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Molecular Cancer Therapeutics
Alessandra BlasinaKenna Anderes

Abstract

Checkpoints are present in all phases of the cell cycle and are regarded as the gatekeepers maintaining the integrity of the genome. Many conventional agents used to treat cancer impart damage to the genome and activate cell cycle checkpoints. Many tumors are defective in the tumor suppressor p53 and therefore lack a functional G(1) checkpoint. In these tumors, however, the S-G(2) checkpoints remain intact and, in response to DNA damage, arrest cell cycle progression allowing time for DNA repair. Checkpoint kinase 1 (Chk1) is a key element in the DNA damage response pathway and plays a crucial role in the S-G(2)-phase checkpoints. Inhibiting Chk1 represents a therapeutic strategy for creating a "synthetic lethal" response by overriding the last checkpoint defense of tumor cells against the lethal damage induced by DNA-directed chemotherapeutic agents. Chk1 inhibition is consistent with emerging targeted therapies aiming to exploit molecular differences between normal and cancer cells. Adding a Chk1 inhibitor to DNA-damaging cytotoxic therapy selectively targets tumors with intrinsic checkpoint defects while minimizing toxicity in checkpoint-competent normal cells. PF-00477736 was identified as a potent, selective ATP-competitiv...Continue Reading

References

Aug 1, 1996·The Journal of Cell Biology·P JinD O Morgan
Oct 6, 1998·Annual Review of Biochemistry·J L Workman, R E Kingston
Nov 1, 2000·Cell·P CheungP Sassone-Corsi
Nov 7, 2000·Current Opinion in Cell Biology·N C Walworth
Dec 2, 2000·Nature·B B Zhou, S J Elledge
Jan 30, 2003·The EMBO Journal·George ZachosDavid A F Gillespie
Dec 13, 2005·Growth Factors·David A ClumpDaniel C Flynn
Jul 18, 2006·Anti-cancer Agents in Medicinal Chemistry·Zhi-Fu Tao, Nan-Horng Lin

❮ Previous
Next ❯

Citations

Dec 10, 2009·Cancer Metastasis Reviews·Simon J Dovedi, Barry R Davies
Jan 25, 2011·Oncogene·N Sangster-GuityF Bunz
Jan 15, 2013·Antioxidants & Redox Signaling·Joy N KavanaghKevin M Prise
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yun Dai, Steven Grant
Apr 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leslie A ParselsMeredith A Morgan
Aug 30, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mike I WaltonMichelle D Garrett
Mar 9, 2011·The Journal of Clinical Investigation·Claire M ConnellIain A McNeish
Jun 13, 2009·Journal of Translational Medicine·David O AzorsaSpyro Mousses
Jan 29, 2013·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Puji AstutiSismindari Sudjadi
Jun 19, 2013·PloS One·M Cris Silva-SantistebanRob L M van Montfort
Feb 19, 2013·Future Oncology·David R Raleigh, Daphne A Haas-Kogan
Oct 22, 2013·Pharmacology & Therapeutics·S McNeelyA K Bence Lin
Dec 24, 2013·Pharmacology & Therapeutics·Todd M PittsErica L Bradshaw-Pierce
Jun 5, 2014·Journal of Radiation Research·Kamrun NaharMasahiko Miura
May 24, 2011·Expert Opinion on Therapeutic Patents·Michael Lainchbury, Ian Collins
May 16, 2009·Expert Opinion on Therapeutic Patents·James W Janetka, Susan Ashwell
Aug 22, 2015·Biomolecules·Jan Benada, Libor Macurek
Dec 17, 2014·Pharmacology & Therapeutics·Anika Maria Weber, Anderson Joseph Ryan
Dec 5, 2012·Cancer Treatment Reviews·M Maugeri-SaccàR De Maria
Oct 31, 2012·Pharmacology & Therapeutics·John M Furgason, El Mustapha Bahassi
Dec 1, 2015·Future Oncology·Elaine M Taylor, Howard D Lindsay
Dec 24, 2011·Drug Discovery Today·Tao ChenNicola J Curtin
Apr 5, 2011·Trends in Pharmacological Sciences·Michelle D Garrett, Ian Collins
Feb 5, 2011·Biochemical and Biophysical Research Communications·Heekyoung YangHae Yong Yoo
Nov 23, 2010·Trends in Molecular Medicine·Cynthia X MaHelen Piwnica-Worms
Nov 25, 2011·Journal of Medicinal Chemistry·John C ReaderIan Collins
Oct 20, 2009·European Journal of Pharmacology·Susanne Burdak-Rothkamm, Kevin M Prise
Jun 13, 2009·The Journal of Investigative Dermatology·Claudia Kerzendorfer, Mark O'Driscoll
Apr 19, 2013·British Journal of Clinical Pharmacology·Ruth Thompson, Alan Eastman
Sep 8, 2010·Environmental and Molecular Mutagenesis·Mats Ljungman
Jun 22, 2010·Bioorganic & Medicinal Chemistry Letters·Thomas P MatthewsIan Collins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Cathy ZhangJames G Christensen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
James B MitchellJohn A Cook
© 2022 Meta ULC. All rights reserved